secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001157523-22-000251
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports Q4 2021 net loss $12.7M, cash $281M; EDG-5506 Phase 1b positive
--------------------------------------------------------------------------------

- Net loss Q4 2021 $12.7M ($0.26/share); full year net loss $42.8M ($1.14/share).
- Cash, equivalents & marketable securities $281M as of Dec 31, 2021.
- Phase 1b EDG-5506 in BMD: CK reduced 71%, TNNI2 reduced 83%; well-tolerated.
- Phase 2 trials planned: BMD in H1 2022, DMD in H2 2022; ARCH open-label study ongoing.
- R&D expenses $32.2M in 2021 (vs $15.0M in 2020); G&A $11.0M (vs $2.2M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322000251/0001157523-22-000251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322000251/a52584668.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer